Emergent BioSolutions (EBS) Total Debt (2016 - 2025)
Historic Total Debt for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $663.1 million.
- Emergent BioSolutions' Total Debt rose 19.64% to $663.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.1 million, marking a year-over-year increase of 19.64%. This contributed to the annual value of $663.7 million for FY2024, which is 4864.5% up from last year.
- According to the latest figures from Q3 2025, Emergent BioSolutions' Total Debt is $663.1 million, which was up 19.64% from $667.8 million recorded in Q2 2025.
- Over the past 5 years, Emergent BioSolutions' Total Debt peaked at $1.0 billion during Q3 2022, and registered a low of $446.5 million during Q4 2023.
- Its 5-year average for Total Debt is $650.9 million, with a median of $663.7 million in 2024.
- Per our database at Business Quant, Emergent BioSolutions' Total Debt plummeted by 5657.4% in 2023 and then surged by 4939.6% in 2025.
- Quarter analysis of 5 years shows Emergent BioSolutions' Total Debt stood at $809.4 million in 2021, then tumbled by 44.59% to $448.5 million in 2022, then fell by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then fell by 0.09% to $663.1 million in 2025.
- Its Total Debt was $663.1 million in Q3 2025, compared to $667.8 million in Q2 2025 and $665.7 million in Q1 2025.